Dr. Marty Makary

So we're actually going to see more access, not less, as some may argue when they say that, you know, R&D is going to take a hit from this. That's going to mean less drugs available. I think you're going to see more availability.

So we're actually going to see more access, not less, as some may argue when they say that, you know, R&D is going to take a hit from this. That's going to mean less drugs available. I think you're going to see more availability.

Is it as simple as that? Yes, it is, because Barack Obama talked about doing this. Bernie Sanders has talked about this a fair bit. Bill Clinton talked about this. As a matter of fact, in his second term, he talked about it a lot.

Is it as simple as that? Yes, it is, because Barack Obama talked about doing this. Bernie Sanders has talked about this a fair bit. Bill Clinton talked about this. As a matter of fact, in his second term, he talked about it a lot.

But all of them came short of actually doing it, because it takes a bold move where you're willing to go up against massive special interests and lobbyists to get this done. But it's also something that... sort of polls very low among the lobbyist community, but polls very high on Main Street among everyday Americans.

But all of them came short of actually doing it, because it takes a bold move where you're willing to go up against massive special interests and lobbyists to get this done. But it's also something that... sort of polls very low among the lobbyist community, but polls very high on Main Street among everyday Americans.

So I think you're going to see some really amazing activity on this, and I'm excited to be a part of it.

So I think you're going to see some really amazing activity on this, and I'm excited to be a part of it.

Well, we're going to see. We're going to work hard at this. There's a lot of things we can do at FDA. One of the main issues in drug pricing is monopoly pricing. So at the FDA, we can do more to bring more generics to market. We can move drugs to over-the-counter where there's more price transparency. And we can also facilitate the generic version of these expensive drugs called biologics.

Well, we're going to see. We're going to work hard at this. There's a lot of things we can do at FDA. One of the main issues in drug pricing is monopoly pricing. So at the FDA, we can do more to bring more generics to market. We can move drugs to over-the-counter where there's more price transparency. And we can also facilitate the generic version of these expensive drugs called biologics.

They're the things that are running nonstop. After I do a TV interview... They, you know, okay, thank you, Dr. McCary, for coming on. And then nonstop ads for these biologics. Why? Is it because there's an epidemic that's new around the conditions that they treat? No, it's because they're gouging Americans and the proxy payers for Americans, their employer groups and their insurance plans.

They're the things that are running nonstop. After I do a TV interview... They, you know, okay, thank you, Dr. McCary, for coming on. And then nonstop ads for these biologics. Why? Is it because there's an epidemic that's new around the conditions that they treat? No, it's because they're gouging Americans and the proxy payers for Americans, their employer groups and their insurance plans.

And so those biologics have generic versions that are much less expensive. They're called biosimilars. And the FDA... has been slow to get those biosimilars to market. There's a lot of reasons for it. We're going to streamline that, and we're going to encourage more biologics. And let's remember, we got the Maha Commission report coming out next Thursday, May 22nd.

And so those biologics have generic versions that are much less expensive. They're called biosimilars. And the FDA... has been slow to get those biosimilars to market. There's a lot of reasons for it. We're going to streamline that, and we're going to encourage more biologics. And let's remember, we got the Maha Commission report coming out next Thursday, May 22nd.

And the best way to lower drug prices in the United States are to stop taking drugs we don't need.

And the best way to lower drug prices in the United States are to stop taking drugs we don't need.

We don't, and it's not helping. The more antidepressants we prescribe, the more depression there is. The more ADHD medications we prescribe, the more ADHD there is. The more opioids that were prescribed, the more opioid addiction there is. I mean, we are going backwards. We're not in a good place. We're watching our nation's kids sick.

We don't, and it's not helping. The more antidepressants we prescribe, the more depression there is. The more ADHD medications we prescribe, the more ADHD there is. The more opioids that were prescribed, the more opioid addiction there is. I mean, we are going backwards. We're not in a good place. We're watching our nation's kids sick.

putting their hand on their belly because they don't feel well. That makes them depressed. It brings on so many problems. There's learning loss. There's all kinds of neurodegenerative disorders that are on the rise. I was told a lot of lies in medical school. One of them was that Alzheimer's was going up because we have an aging population that's expanding. Well, guess what?

putting their hand on their belly because they don't feel well. That makes them depressed. It brings on so many problems. There's learning loss. There's all kinds of neurodegenerative disorders that are on the rise. I was told a lot of lies in medical school. One of them was that Alzheimer's was going up because we have an aging population that's expanding. Well, guess what?